China's API extortion from Indian pharma breaking down
The API coming from China started getting dumped in India at very low prices.
The API coming from China started getting dumped in India at very low prices.
India imported ₹35,000 crore worth of APIs and bulk drugs in FY22, accounting for 35% of its total API requirement, of which China accounted for 65-70% share.
With several years of experience in the pharma industry, Satyanarayana Chava has catapulted Laurus among the top global R&D firms.
The problems faced by FDA’s investigators in India are similar to those around the world, US Food and Drug Administration spokesperson Jeremy Kahn tells Fortune India.
The Covid-19 disruption has ignited a new era of value-based customer-centric banking. It has also given rise to platform and data-driven approaches, signalling a radical change in retail banking.
Route Mobile, a cloud communications platform for enterprises, has had a dream run on the bourses since its listing last year. At the core of this success is the humble text message.
Founded in Bengaluru and now headquartered in San Francisco, Postman’s Series B round of fundraise will further accelerate its growth in the API ecosystem.